Dren Bio, Inc.
FOSTER CITY, CA · Founded 2019 · CIK 0001783374 · Biotech · Private
Engineered therapeutic antibodies for selective targeting and depletion of disease-causing cells and agents
drenbio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $93M
- 3 Form D · Mar 2022
- 54 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 33
- 2 granted · 31 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,054,991 | |
| Private capital raised | Form D · SEC | $25,499,996 | |
| Private capital raised | Form D · SEC | $62,500,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2275 | EdenRoc Sciences LLC | — | $194M |
| 2276 | ENGAGE BIOLOGICS INC. | — | — |
| 2277 | Perfect Day, Inc. | — | $222M |
| 2278 | Dren Bio, Inc. | — | $93M |
| 2279 | CURAVAC, INC. | — | $4.7M |
| 2280 | bluebird bio | — | $179M |
| 2281 | EFFECTORBIO, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Sakae AsanumaDirector
- Rajeev DadooDirector
- Alex KolicichDirector
- Chandra LeoDirector
- Kenneth LuehrsenDirector
- Andrew SchiffDirector
- Nenad TomasevicDirector · Executive Officer
- Ivan TrifunovichDirector
- John WesleyDirector
Patents
- ANTI-DECTIN-1 Antibodies And Methods Of Use Thereofapplication
- Methods Of Depleting Disease Causing Agents Via Antibody Targeted Phagocytosisapplication
- ANTI-DECTIN-1 Antibodies And Methods Of Use Thereofgranted
- ANTI-CD94 Antibodies And Methods Of Use Thereofgranted
- Methods Of Reducing Large Granular Lymphocyte And Natural Killer Cell Levelsapplication
- Methods Of Depleting Disease Causing Agents Via Antibody Targeted Phagocytosisapplication
- Multispecific Antibodies And Methods Of Use Thereofapplication
- ANTI-CD94 Antibodies And Methods Of Use Thereofapplication
- Multispecific Binding Proteins That Bind DECTIN-1 And TROP-2 And Methods Of Use Thereofapplication
- Multispecific Binding Proteins That Bind DECTIN-1 And CD20 And Methods Of Use Thereofapplication
- ANTI-DECTIN-1 Antibodies And Methods Of Use Thereofapplication
- ANTI-CD94 Antibodies And Methods Of Use Thereofapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.